AzTrials
AzTrials

Urinary RetentionEvaNCT05065255

Study of the Criteria for Choosing Speedicath Catheters During the Initiation of Self-catheterization

An observational study of Urinary Retention, run by Laboratoires Coloplast S.A.S at 38 sites in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

To date, there is no objective data to help in the choice of the type of catheter to offer to the patient according to his or her needs. Although it is now known that the quality of life of patients practicing intermittent self catheterisation is dependent on multiple factors, there is little data on the factors that… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Urinary Retention
What is being tested?
SpeediCath® catheters
Type of treatment
Medical device
How many people
250 participants
Where
38 sitesFrance
Study dates
30 Sep 2021to 30 Jan 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study will be offered to all adult subjects with neurogenic or non-neurogenic urinary disorders, newly initiated to ISC, and using the SpeediCath line of catheters.

Who may be able to join

  • Female or male, 18 years of age or older
  • Subject having been informed of the study and having decided to participate (no opposition)
  • Subject affiliated to a social security system or entitled to it
  • Subject with neurogenic or non-neurogenic urinary disorders, justifying the use of the ISC to empty the bladder
  • Subjects who have received their first ISC education at the time of inclusion
  • Subject with an expected duration of ISC of at least 6 months
Show all 9Show fewer
  • Subject has been presented with at least two types of SC catheters and has chosen to use the SpeediCath line of catheters as their first self-catheterization catheter
  • Able to perform ISC independently
  • Subjects who have been recommended by their healthcare professional to perform catheterization at least 4 times per day

Who cannot join

  • Vulnerable subject according to the regulations in force
  • Pregnant, parturient or nursing woman;
  • Subject deprived of liberty by judicial, medical or administrative decision;
  • Minor subject ;
  • Subject protected by law or unable to give consent
  • Subject who is not affiliated or not a beneficiary of a social security system;
Show all 10Show fewer
  • Subject falling into several of the above categories;
  • Subject who has refused to participate in the study
  • Subject participating in an interventional clinical study
  • Subjects who, in the opinion of the investigator, have cognitive problems that prevent them from answering a questionnaire or for whom assessment could be problematic.

Trial locations and contacts

38 sites in 1 country.

Souad MEILLASSOUX, MD contact

+33 1 56 63 17 81

frsme@coloplast.com

Murielle Loock contact

frmlk@coloplast.com

38 sites in 1 country

France38 sites, 38 recruiting
  • Centre hospitalier d'Aulnay sous bois

    Aulnay-sous-Bois

    Béatrice Davenne

    Not yet recruiting
  • Centre Hospitalier Intercommunal Robert Ballanger

    Aulnay-sous-Bois

    Emmanuel Van Glabeke

    Not yet recruiting
  • Centre auterive

    Auterive

    Sophie Rouleaud

    Recruiting
  • Centre Calvé- Fondation Hopale

    Berck

    Jean Gabriel Prévinaire

    Not yet recruiting
  • Tour de Gassies

    Bruges

    Amandine Grelier

    Not yet recruiting
  • CHU de Caen

    Caen

    Antoine Desvergée

    Not yet recruiting
  • Centre Hospitalier William Morey

    Chalon-sur-Saône

    Nicolas Koutlidis

    Not yet recruiting
  • Centre médical Germaine Revel

    Chamalières

    Vivien Reynaud

    Not yet recruiting
  • Hôpitaux civil de Colmar

    Colmar

    Amine Messaoudi

    Not yet recruiting
  • CHU Le Bocage

    Dijon

    Céline Duperron

    Recruiting
  • Hôpital Raymond Poincaré

    Garches

    Alexia Even

    Not yet recruiting
  • Centre Hospitalier de Gonesse

    Gonesse

    Mohamed Marouane Hmida

    Not yet recruiting
  • CHU GrenobleAlpes

    La Tronche

    Caroline Thuillier

    Not yet recruiting
  • Hôpital Swynghedauw

    Lille

    Anne Blanchard

    Not yet recruiting
  • CHU Limoges

    Limoges

    Aurelien Descazeaud

    Not yet recruiting
  • Clinique Saint Martin

    Marseille

    Karine Lenne Aurier

    Not yet recruiting
  • CHU de Timonnes

    Marsillargues

    Camino Muro Guerra

    Not yet recruiting
  • Hôpital Lapeyronie

    Montpellier

    Laurent Cabaniols

    Not yet recruiting
  • Institut Mutualiste Montpelliérain- Beau soleil

    Montpellier

    Grégoire Poinas

    Not yet recruiting
  • CHU de Nancy

    Nancy

    Pierre Lecoanet

    Recruiting
  • Hôpital Saint jacques

    Nantes

    Bénédicte Reiss

    Recruiting
  • Hôpital Pasteur 2 - CHU de Nice

    Nice

    Imad Bentellis

    Not yet recruiting
  • Hôpital Tenon

    Paris

    Gérard Amarenco

    Not yet recruiting
  • Hôpital Universitaire Pitié-Salpêtrière

    Paris

    Emmanuel Chartier-Kastler

    Not yet recruiting
  • Centre PSR

    Perpignan

    Redha Benbouzid

    Not yet recruiting
  • CMMRF Kerpape

    Ploemeur

    Jacques Kerdraon

    Not yet recruiting
  • CHU Reims

    Reims

    Richard Seret

    Not yet recruiting
  • CHU Rennes

    Rennes

    Benoit Peyronnet

    Not yet recruiting
  • Hôpital Victor Provo

    Roubaix

    François Pecoux

    Not yet recruiting
  • CHU Rouen

    Rouen

    Jean-Nicolas CORNU

    Not yet recruiting
  • Hopital Charles Nicolle

    Rouen

    Maximilien Baron

    Not yet recruiting
  • Hôpital Bellevue, CHU de SAINT ETIENNE

    Saint-Etienne

    Julia Touly

    Not yet recruiting
  • Hôpital Henry Gabrielle

    Saint-Genis-Laval

    Amandine Guinet-Lacoste

    Recruiting
  • Hôpital Henry Gabrielle

    Saint-Genis-Laval

    Damien Waz

    Not yet recruiting
  • Centre de l'Arche

    Saint-Saturnin

    Gaelle Audat

    Not yet recruiting
  • Nouvel Hôpital Civil

    Strasbourg

    Thibault Tricard

    Not yet recruiting
  • CHU Toulouse Rangueil

    Toulouse

    Xavier Game

    Recruiting
  • CHU Tours

    Tours

    Franck Bruyère

    Not yet recruiting

Other trials in France

About this study

To date, there is no objective data to help in the choice of the type of catheter to offer to the patient according to his or her needs. Although it is now known that the quality of life of patients practicing intermittent self catheterisation is dependent on multiple factors, there is little data on the factors that facilitate or hinder adherence to intermittent self catheterisation during the first six months after initiation of intermittent self catheterisation. The prospective multicenter exploratory observational study that the sponsor wishes to conduct aims to determine what criteria preside over patient choice of SpeedyCath (SC) leads. This information would allow us to set up a personalized advice with each patient in the future, with the aim of proposing the SC catheter best adapted to his needs. The study population will consist of adults with neurogenic or non-neurogenic urinary disorders that warrant the use of intermittent self catheterisation, with intermittent self catheterisation education occurring at the time of inclusion. Patients should be autonomous in the practice of intermittent self catheterisation, and the minimum expected duration of follow-up should be greater than or equal to 6 months. Only patients who choose to use SpeediCath leads will be included in the study.

Read the detailed description

Urinary self-catheterization consists of emptying the bladder oneself by inserting a catheter into the urethra. It is the reference method in case of dysfunctions of the bladder emptying phase, in particular in case of complete urinary retention or complete or incomplete bladder emptying with sub bladder obstruction. Neurological pathologies such as spinal cord injury, multiple sclerosis, multisystematic atrophy, peripheral neuropathies, Parkinson's disease, and stroke, may be the cause of bladder disturbances. These disturbances may also be caused by pelvic denervations as a result of enlarged pelvic surgeries or radiotherapy for the treatment of gynecological, urological or digestive cancers.

The objective of the implementation of intermittent self-catheterization (ISC) is to reduce the morbidity related to bladder and bowel dysfunction and to improve the quality of life of patients by making them more autonomous.

It involves a rigorous learning phase for the patient and a phase of acceptance of this new mictional mode.

When ISC is indicated, training is provided to the patient to enable him/her to manage daily catheterization. The objectives of this training are to understand, perform, monitor and adapt self-care. This training, mainly provided by the nursing staff and/or a specialist physician, is usually provided during a hospitalization. After returning home, the patient continues to be monitored by the specialist physician and the nursing team to evaluate the mastery of the technique (possibly reviewing the gesture and ensuring the adequacy of the catheter), the patient's adaptation to the practice of ISC, his compliance with the associated rules (frequency and regularity of catheterization, volume of urine) and any complications. A first visit is usually made between 3 and 12 weeks, then a second one after 6 months of use.

However, this therapeutic patient education (TPE), even when carried out by trained personnel, is not necessarily sufficient for immediate acceptance and adherence to self-catheterization in the medium to long term.

It is important that the patient is involved in his or her choice of equipment, since the decision to self-catheterize is usually made by the physician, and that the benefits of self-catheterization outweigh the constraints. The patient must be guided and involved in the choice of catheter during this learning phase, which will ensure better compliance and future adherence to treatment.

The interest of this study is therefore to better understand the real motivations of the patient in the choice of the catheter. This will undoubtedly make it possible to improve either the equipment itself or certain FTE sequences in the future by insisting on the problematic or questioning points in terms of the choice of catheter proposed to the patient by the caregiver. The determinants of the patient's choice are all the more important as there are a very large number of catheters on the market.

Coloplast offers the SpeediCath® (SC) range of ready-to-use self-lubricating hydrophilic catheters. This range is designed to cover the different needs of patients, providing them with probes of different length, flexibility, shape and ergonomics. There are 3 types of catheters adapted to women (SC Standard®, SC Compact® and SC Compact Set, SC Compact Eve®), and 3 types of catheters adapted to men (SC Standard®, SC Compact® and SC Compact Set, SC Flex®).

Concerning the technical specificities, a systematic review of the literature concluded that hydrophilic catheters (with a lubricant attached to the catheter) provide a benefit in terms of safety and quality of life, particularly in patients with spinal cord injuries. SC® catheters significantly reduce trauma to the urinary tract by reducing friction. Another study also showed that SpeediCath catheters were significantly faster, more convenient, and more discreet to use than a non-ready-to-use hydrophilic catheter (need to activate lubricant). The superiority of SpeediCath Compact Male and Female catheters in terms of quality of life compared to reference catheters was demonstrated in a randomized study using the specific validated ISC-Q questionnaire and has been retained and valued by the CNEDiMTS

To date, there is no objective data to help in the choice of the type of catheter to propose to the patient according to his needs. Although it is now known that the quality of life of patients using ISC is dependent on multiple factors, there is little data on the factors that facilitate or hinder adherence to ISC during the first six months after initiation of ISC. The prospective multicenter exploratory observational study that the sponsor wishes to conduct aims to determine the criteria that govern patient choice of SC leads. This information would allow us to set up a personalized advice with each patient in the future, with the aim of proposing the SC catheter best adapted to his needs. The study population will consist of adults with neurogenic or non-neurogenic urinary disorders that warrant the use of ISC, with ISC education occurring at the time of inclusion. Patients should be autonomous in the practice of ISC, and the minimum expected duration of follow-up should be greater than or equal to 6 months. Only patients who have chosen to use SpeediCath leads will be included in the study.

Numerous criteria will be collected to allow a detailed analysis of the modalities of choice of the type of SC probe. This collection involves the use of self-questionnaires for the patients. These questionnaires will be collected during the usual follow-up of the patient, including a visit at the time of the ASI education, a follow-up visit around 3 to 12 weeks (depending on the practices of the investigating center) and a second follow-up visit around 6 months.

Acceptance of ISC will be measured by the Intermittent Catheterization Acceptance Test (I-CAT). This is a patient questionnaire developed by the Groupe d'Études de Neuro-Urologie de Langue Française (GENULF) and validated in French in 2016 during a prospective multicenter study of 201 neurological and non-neurological patients. The I-CAT allows for a better assessment and understanding of the psychological barriers encountered by patients in relation to ISC. The questionnaire consists of 14 questions, with a minimum score of 0 for perfect acceptance and a maximum score of 56 characterizing the least possible acceptance.

The difficulties encountered by patients during ASI will be measured by the "Intermittent Catheterization Difficulty Questionnaire" IC-Di-Q. This is a patient questionnaire validated in French, and its purpose is to evaluate the difficulties encountered during the performance of ISA. In 13 questions, it explores numerous factors such as pain, blockage, bleeding, spasticity, and urethral sphincter spasm, in terms of frequency of occurrence and intensity. The purpose of this questionnaire is to identify the difficulties encountered by patients, and to monitor their evolution after the implementation of alternatives or solutions (including the adaptation of the type of catheter).

Patient adherence to ISC will be measured by the Intermittent Catheterization Adherence Scale (I-CAS). This is a patient questionnaire validated in French with 8 questions, 7 of which have a binary answer (yes/no), and one with 5 suggested answers. The score ranges from 0 for strong adherence to ISC to 8 for very weak adherence.

A study-specific self-questionnaire was also created with the support of the Scientific Advisory Board to determine the reasons for the patient's choice of catheter. This questionnaire includes criteria independent of the patient (e.g. advice from the nurse), and criteria specific to the patient (e.g. ease of use, discretion).

Being tested
SpeediCath® catheters
Medical subject headings
Urinary Retention

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SpeediCath® cathetersDevice

    Patients using SC catheters will be followed up in order to understand the major criteria in the choice of the catheter by the patients.

Study groups in NCT05065255
Study groupRoleWhat they receive
PatientsAdult subjects with neurogenic or non-neurogenic urinary tract disorders, newly initiated to ASI, and users of the SpeediCath line of catheters.
Receives: Device: SpeediCath® catheters

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Patient questionnaire for the choice of the catheter

    A study-specific self-administered questionnaire was created with the support of the Scientific Advisory Board to determine the reasons for the patient's choice of catheter. This questionnaire contains 18 questions, including criteria independent of the patient (e.g. advice from the nurse), and criteria specific to the patient (e.g. ease of use, discretion).

    Measured: At visit 3 : 6 months

Secondary outcomes (8)
  1. Patient questionnaire for the choice of the catheter

    A study-specific self-administered questionnaire was created with the support of the Scientific Advisory Board to determine the reasons for the patient's choice of catheter. This questionnaire contains 18 questions, including criteria independent of the patient (e.g. advice from the nurse), and criteria specific to the patient (e.g. ease of use, discretion).

    Measured: At baseline

  2. Patient satisfaction

    Determined by a 0 to 5 points visual analog scale, 0 is the worst possible satisfaction, and 5 is the best possible satisfaction

    Measured: At visit 2 : 3 to 12 weeks

  3. Patient satisfaction

    Determined by a 0 to 5 points visual analog scale, 0 is the worst possible satisfaction, and 5 is the best possible satisfaction

    Measured: At visit 3 : 6 months

  4. "Intermittent Catheterization Difficulty Questionnaire" IC-Di-Q

    This is a patient questionnaire validated in French.The purpose of this questionnaire is to identify the difficulties encountered by the patients and to follow their evolution after the implementation of alternatives or solutions (including the adaptation of the type of catheter). In 13 questions, it explores numerous factors such as pain, blockage, bleeding, spasticity, and urethral sphincter spasm, in terms of frequency of occurrence and intensity.

    Measured: At visit 2 : 3 to 12 weeks

  5. "Intermittent Catheterization Difficulty Questionnaire" IC-Di-Q

    This is a patient questionnaire validated in French.The purpose of this questionnaire is to identify the difficulties encountered by the patients and to follow their evolution after the implementation of alternatives or solutions (including the adaptation of the type of catheter). In 13 questions, it explores numerous factors such as pain, blockage, bleeding, spasticity, and urethral sphincter spasm, in terms of frequency of occurrence and intensity.

    Measured: At visit 3 : 6 months

  6. Catheterization Adherence Scale (I-CAS)

    This is a patient questionnaire validated in French with 8 questions, 7 of which have a binary response (yes/no), and one with 5 suggested answers. The score ranges from 0 for strong adherence to ASI to 8 for very weak adherence.

    Measured: At visit 2 : 3 to 12 weeks

  7. Catheterization Adherence Scale (I-CAS)

    This is a patient questionnaire validated in French with 8 questions, 7 of which have a binary response (yes/no), and one with 5 suggested answers. The score ranges from 0 for strong adherence to ASI to 8 for very weak adherence.

    Measured: At visit 3 : 6 months

  8. Intermittent Catheterization Acceptance Test (I-CAT) questionnaire

    The I-CAT allows for a better assessment and understanding of the psychological barriers encountered by patients in relation to ISA. The questionnaire consists of 14 questions, with a minimum score of 0 for perfect acceptance and a maximum score of 56 characterizing the least possible acceptance.

    Measured: At baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Oct 2021
  2. Study start30 Sep 2021
  3. Primary completion30 Jan 2023 (estimated)
  4. Study completion30 Jan 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
250 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05065255
Sponsor's protocol ID
2021-A00579-32
Acronym
Eva
Status last verified
Mar 2022
First submitted
10 Aug 2021
Last updated
11 Mar 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Urinary Retention, run by Laboratoires Coloplast S.A.S at 38 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 11 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 38 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Souad MEILLASSOUX, MD (+33 1 56 63 17 81, frsme@coloplast.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Patient questionnaire for the choice of the catheter (time frame: At visit 3 : 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Mar 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in